In the late 1980s — when Prozac had been on the market for just two years — something deeply disturbing surfaced in unpublished Phase 1 trials.

And it was something no drug company wants to see.

Healthy volunteers — people with no history of depression — were developing a side effect that wouldn’t go away...

Even after they stopped taking the drug.

By 1991, the UK’s drug regulator had received its first formal report.

The problem? Persistent sexual dysfunction linked to fluoxetine.

You’d think that would have triggered alarm bells.

After all, this wasn’t simply a headache, nausea, or some other temporary reaction. People were reporting sexual problems that continued long after the drug was out of their system.

Yet for more than three decades, the official message passed from the pharmaceutical industry to your doctor — and from your doctor to you — remained the same:

“Side effects are temporary. They’ll resolve when you stop the medication.”

Then, in 2024, a government regulator finally broke ranks.

Australia’s Therapeutic Goods Administration — the equivalent of our FDA — mandated a new warning for SSRI and SNRI antidepressants.

These drugs can cause sexual dysfunction that persists for weeks, months, years — or permanently — after you stop taking them.¹

The condition now has a name.

It’s called Post-SSRI Sexual Dysfunction, or PSSD. And it includes symptoms that would horrify any man or woman: complete genital numbness, as though you’d been injected with novocaine below the waist.

The total disappearance of sexual desire... Erectile failure that doesn’t respond to Viagra or Cialis... Orgasms that feel like nothing — if they happen at all.

So how did this go unaddressed for so long?

Because drug makers rigged the way they measured side effects.

In their original clinical trials, pharmaceutical companies relied on what’s called “unprompted reporting.” They didn’t ask patients about sexual problems. They waited for patients to volunteer the information.

Imagine sitting across from your doctor — a stranger in a white coat — and volunteering that you can’t achieve an erection or that your genitals have gone numb.

Of course, almost no one did. And so the early trials reported sexual side effects in fewer than 10% of patients.

It was the perfect cover-up.

But when independent researchers finally had the courage to ask patients directly, the real numbers detonated like a bomb.

In the largest prospective study ever conducted on this question, Dr. Angel Luis Montejo and his team enrolled 1,022 outpatients across multiple centers in Spain. They didn’t wait for patients to complain. They asked directly. And the results were staggering.

The overall incidence of sexual dysfunction across all SSRIs was 59%. But for individual drugs, the numbers were even worse...

And citalopram — one of the most commonly prescribed antidepressants in America — came in at 73%.²

Compare that to 4% for moclobemide, a reversible MAOI that doesn’t target serotonin the way SSRIs do.

The difference is not subtle. It’s a canyon.

And the data has only gotten worse with time. A 2025 study found that 84.5% of men

and 89% of women taking antidepressants reported some degree of sexual dysfunction.³

That’s not just a side effect... That’s the main effect.

But here’s the part that should keep every SSRI user awake at night: For a significant number of people, the damage doesn’t go away when the drug is stopped.

When Montejo’s team switched patients from SSRIs to amineptine — an older antidepressant that doesn’t affect serotonin — 55% of those patients still had sexual dysfunction six months later.⁴

The SSRI was gone from their bodies. But the damage it left behind was not.

A separate placebo-controlled study found that sertraline’s ejaculation-delaying effect persisted in 34% of participants six months after they stopped taking the drug.⁵

Think about that. Half a year later, with no drug in their system, more than a third of these men were still experiencing a side effect from a pill they’d stopped taking.

The most rigorous population-level data comes from a landmark 2023 Israeli study. Researchers analyzed 19 years of medical records from the country’s largest health maintenance organization.

After excluding every possible confounding factor — age, weight, depression, and anxiety — they found that serotonergic antidepressants were associated with a 3.2-fold increased risk of erectile dysfunction. And PSSD — permanent, irreversible sexual dysfunction — developed in approximately one out of every 216 treated patients.⁶

One in 216. In a country where tens of millions of prescriptions are written every year, that translates to a staggering number of victims.

And only 10% to 15% of patients who develop SSRI-associated sexual dysfunction report any significant improvement after six to 12 months.⁷ For the rest, the clock just keeps ticking.

Here is what the pharmaceutical industry doesn’t tell you:

There is no FDA-approved treatment for PSSD. None. The system that caused the damage has absolutely no solution for it.

The European Medicines Agency issued label changes in 2019. Health Canada followed in 2021. Australia’s TGA acted in 2024. Diagnostic criteria for PSSD were published in 2022. A formal diagnostic code — called a SNOMED CT code — was introduced in 2024 so the condition can finally be recorded in electronic health records.⁸

This is no longer a fringe theory. It’s mainstream science. The only thing that isn’t mainstream is the medical establishment’s willingness to act on it.

Now I need to explain why this happens. Because once you understand the mechanism, you’ll understand why Viagra doesn’t work for PSSD — and why natural solutions that address the root cause are your best hope.

Your doctor was taught that SSRIs simply “block serotonin reuptake.” They increase the amount of serotonin floating around in your synapses. When you stop the drug, the thinking goes, everything goes back to baseline.

Except it doesn’t.

Because SSRIs do something far more insidious than temporarily tweaking a neurotransmitter.

With chronic use, they trigger epigenetic changes — modifications that alter how your genes are expressed without changing your DNA code itself.

Think of your DNA as a piano. The keys are always there. But epigenetic changes are like someone gluing certain keys down, or muting certain strings. The instrument looks the same, but it plays a completely different tune.

Researchers have identified the specific mechanism. A landmark study found that chronic fluoxetine treatment induces the production of proteins called MeCP2 and MBD1 in the brain.

These are proteins that act like a mute button on your genes — attaching to your DNA and shutting down gene expression. The modifications were found in three key areas of the brain involved in mood, memory, and reward.⁹

This is accompanied by enhanced production of another protein that locks down gene activity — clamping down further on how your cells function.

These aren’t temporary changes. They’re etched into the very architecture of your brain cells.

The result? Persistent desensitization of your 5-HT1A receptors — the same receptors that regulate sexual desire, arousal, and orgasm — that remains even after the drug is completely eliminated from your body.

But it gets worse...

There’s a crucial interaction between serotonin and dopamine that your doctor probably never learned about. Excess serotonin suppresses dopamine signaling in the brain’s pleasure and reward circuit — the very system responsible for pleasure, desire, and sexual motivation.

When that suppression becomes permanently locked into your brain chemistry, it doesn’t matter how much blood flow you send to the genitals.

Viagra and Cialis work on blood vessels. PSSD is a neurological and genetic injury.¹⁰

Animal research confirms this beyond any reasonable doubt. A systematic review of 14 placebo-controlled trials in rodents found that early SSRI exposure produced permanent sexual dysfunction.

Brain analysis showed lasting reductions in the key enzymes the body uses to make serotonin — changes that persisted long after the drug was gone.¹¹

Doctors may tell you the problem is “in your head.” And they’re right — but not the way they really mean it.

The problem is in your gene expression, etched into the architecture of your brain cells by a drug that was supposed to help you.

Here’s what you can do about it...

Big Pharma has no solution for PSSD. But that doesn’t mean there is no solution. It means the solution doesn’t come in a patented pill, so no drug company will ever spend a dime promoting it.

I’ve seen this in my own clinic — patients who came to me after years of suffering with these symptoms, dismissed by every doctor they’d seen. What I’m sharing with you now is exactly what

I recommend to them: three natural solutions to help your body recover.

1.      Spice Up Your Recovery With Saffron. Of all the natural compounds I’ve studied for this condition, saffron has the strongest clinical evidence. Not the saffron you sprinkle on rice — a concentrated, standardized extract.

In a randomized, double-blind, placebo-controlled trial, men taking fluoxetine who received saffron extract — just 15 mg twice daily — experienced significantly greater improvement in erectile function and intercourse satisfaction compared to those receiving placebo, in just four weeks.¹²

A parallel trial in women on fluoxetine found significant improvement in arousal, lubrication, and pain after the same four weeks.¹³

A 2019 analysis pooling five studies and 173 participants found that saffron consistently improved sexual function across the board.¹⁴

When shopping for saffron, check the label. Many supplements are standardized to safranal — the compound responsible for saffron’s distinctive aroma — but the research shows it’s crocin that drives the sexual benefits.

Look for a product that specifies standardization to crocin. Take 15 mg twice daily — 30 mg total.

2.      Supercharge Your Dose With Maca. The Inca warriors reportedly consumed maca before battle for strength and stamina. Modern science suggests they were onto something — but dose is everything.

In one study, patients taking 3,000 mg of maca per day saw significant improvement in sexual function. Those taking half that dose — 1,500 mg — did not.¹⁵

A follow-up trial found the same 3,000 mg daily dose improved orgasmic function in women with SSRI-induced dysfunction.¹⁶

Don’t waste your money on a 500 mg capsule. The research is clear: You need 3,000 mg a day, minimum. And unlike prescription erectile dysfunction drugs, maca has a safety profile that makes it suitable for older adults and cardiac patients who can’t take those medications.

3.      Build Your Nutritional Foundation. No targeted protocol can work at full capacity if your body lacks the raw materials for healthy neurotransmitter production. These are not standalone PSSD treatments.

But they fill the nutritional gaps that make the problem worse, and they give your body what it needs to get the most out of these steps.

I recommend three foundational nutrients:

To Your Good Health,

Al Sears, MD, CNS

1. Therapeutic Goods Administration. “Updated warnings about persistent sexual dysfunction for antidepressants.” TGA Medicines Safety Update. 23 May 2024.

2. Montejo AL, et al. “Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients.” J Clin Psychiatry. 2001; 62(Suppl 3):10–21.

3. Safak Y, Inal Azizoglu S, Alptekin FB, et al. “Antidepressant-associated sexual dysfunction in outpatients.” BMC Psychiatry. 2025;25(1):317.

4. Montejo AL, et al. “Sexual dysfunction with antidepressive agents. Effect of the change to amineptine in patients with sexual dysfunction secondary to SSRI.” Actas Espanolas de Psiquiatria. 1999; 27(1):23–34.

5. Arafa M, Shamloul R. “Efficacy of sertraline hydrochloride in treatment of premature ejaculation: a placebo-controlled study using a validated questionnaire.” Int J Impotence Res. 2006; 18(6):534–538.

6. Ben-Sheetrit J, et al. “Estimating the risk of irreversible post-SSRI sexual dysfunction (PSSD) due to serotonergic antidepressants.” Ann Gen Psychiatry. 2023; 22(1):15.

7. Osis L, et al. “Pharmacogenetics of SSRIs and sexual dysfunction.” Pharmaceuticals (Basel). 2010; 3(12):3614–3628.

8. Healy D, Mangin D. “Post-SSRI sexual dysfunction: barriers to quantifying incidence and prevalence.” Epidemiol Psychiatr Sci. 2024; 33:e40.

9. Cassel S, et al. “Fluoxetine and cocaine induce the epigenetic factors MeCP2 and MBD1 in adult rat brain.” Mol Pharmacol. 2006; 70(2):487–492.

10. Bala A, et al. “Post-SSRI sexual dysfunction: a literature review.” Sex Med Rev. 2018; 6(1):29–34.

11. Simonsen AL, et al. “Persistent sexual dysfunction after early exposure to SSRIs: systematic review of animal studies.” Int J Risk Saf Med. 2016; 28(1):1–12.

12. Modabbernia A, et al. “Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial.” Psychopharmacology. 2012; 223(4):381–388.

13. Kashani L, et al. “Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study.” Hum Psychopharmacol. 2013; 28(1):54–60.

14. Ranjbar H, et al. “Effects of saffron (Crocus sativus) on sexual dysfunction among men and women: a systematic review and meta-analysis.” Avicenna J Phytomed. 2019; 9(5):419–427.

15. Dording CM, et al. “A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction.” CNS Neurosci Ther. 2008; 14(3):182–191.

16. Dording CM, et al. “A double-blind placebo-controlled trial of maca root as treatment for antidepressant-induced sexual dysfunction in women.” Evid Based Complement Alternat Med. 2015; 2015:949036.Mumtaz H, et al. “Association of vitamin B12 deficiency with long-term PPIs use: a cohort study.” Annals of Medicine and Surgery. 2022; 82:104762.